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Background: There has been resurgence in the use of Percutaneous Aortic Balloon
Valvotomy (PABV) in patients at high surgical risk due to development of less
invasive endovascular therapies. We determined the outcomes of concomitant
PABV and percutaneous coronary intervention (PCI) during same hospitalization
and compared them to PABV alone using the nation’s largest hospitalization
database.
Methods: This is a cross-sectional study with time trends using the Nationwide
Inpatient Sample database between the years 1998-2010. We identiﬁed patients
using the International Classiﬁcation of Diseases, 9th Revision, Clinical Modi-
ﬁcation procedure code for valvotomy. Only patients >60 years of age with
aortic stenosis were included. Primary outcome included in-hospital mortality
and secondary outcomes included procedural complications and length of hos-
pital stay
Results: A total of 2,127 PABV procedures were identiﬁed of which 247 were PABV
+ PCI (PABV + PCI group) and 1,880 (weighted N ¼ 9411) were PABVs alone
(PABV group). Majority (69%) of the patients in PABV + PCI group were >80 years
old with equal representation from both genders. The utilization rate of concomitant
PABV + PCI during the same hospitalization has signiﬁcantly increased by 225%
from 5.1% in 1998-1999 to 16.6% in 2009-2010 in US (p < 0.001). Overall in-
hospital mortality rate in the PABV + PCI group was identical to that of the PABV
group (10.3% vs 10.5%). The overall complications rates were also similar in PABV +
PCI vs PABV group (28% vs 29.1%). Patients in the PABV + PCI group had
signiﬁcantly longer stay [median (interquartile range)] in the hospital [7(3-14) vs 5(2-
11) days, p < 0.001) and increased cost of hospitalization [$30,089($21,925 -
$48,267) vs $18,421($11,482 - $32,215), p < 0.001) when compared to those
of PABV group. The signiﬁcant predictors of increased LOS and cost of hospital
admission were unstable condition, occurrence of any complication, weekend
admission and low operator volume.
Conclusions: Concomitant PCI and PABV during the same hospitalization does not
increase in-hospital mortality or complications rate when compared to PABV however
it increases length of hospital stay and cost of hospitalization.TCT-787
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Background: The increased prevalence of transcatheter aortic valve replacement
(TAVR) has brought a renewed interest in the role for balloon aortic valvuloplastyB230 JACC Vol 64/11/Suppl B j September 13–17, 201(BAV) in the management of patients with severe aortic stenosis (AS). The current
study is a prospective study of BAV analyzed by intent-to-treat.
Methods: This is a study of 100 patients undergoing BAV for management of
severe AS. Before the procedure, physicians assigned intent of BAV as 1) bridge to
decision for treatment (BTD); 2) therapeutic bridge to planned therapy (BTX); or
3) palliation (PAL). Patients were followed up to 1 year, with outcomes including
quality of life as measured by the Kansas City Cardiomyopathy Questionnaires
(KCCQ).
Results: Intent in 84 of the planned 100 patients currently enrolled is shown in the
ﬁgure: 62 BTD; 18 BTX; and 4 PAL. 30-day mortality for all patients was 5/84
(6.0%). Two of these patients were in the palliative cohort. Other complications
included cerebrovascular accident 2/84 (2.4%) and acute kidney injury 5/84 (6.0%).
Mean follow-up was 124.091.9 days. Treatment outcomes after BAV are shown
in the ﬁgure. Of all patients surviving to 30 days without having received a
valve (n¼43), summary KCCQ score increased from 40.0922.05 at baseline to
49.4924.04 at 30 days (p¼0.67).
Conclusions: Prior to deﬁnitive treatment, patients saw a non-signiﬁcant improve-
ment in quality of life at 30 days. 61.1% (11/18) BTX patients and 30.6% (19/62)
BTD patients went on to undergo aortic valve replacement. BAV has evolved as a
diagnostic tool to aid in decision-making for TAVR candidacy.Valvular disease - Mitraclip
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Background: Among patients with signiﬁcant functional mitral regurgitation (FMR),
surgery is not always indicated and medical therapy may provide limited relief.
Cardiac resynchronization therapy (CRT) reduces FMR in some but not all patients.
This analysis describes improvements observed following treatment with MitraClip
in high risk FMR patients who were symptomatic despite CRT.
Methods: EVEREST II high risk patients with MR3+ who were NYHA Class III/IV
at study entry despite CRT-D or CRT-P implantation were analyzed. Patients eligible
for MitraClip had left ventricular (LV) dysfunction with LVESD 60 mm and LVEF
20%. One-year outcomes included NYHA Class, Quality of Life (QoL), heart failure
(HF) hospitalizations and echocardiographic measures analyzed by an independent
core lab.
Results: A total of 48 symptomatic high risk FMR patients (mean age 74 yrs) with CRT
underwent theMitraClip procedure. Baseline co-morbidities includedCAD (88%), prior
CV surgery (67%) and moderate-severe renal disease (35%). LVEF pre-MitraClip was
389%. Predicted mortality by STS risk score was 11.57.5%. Observed 30-day
mortalitywas 6%.MR reduction to2+was observed in 78%of CRT patients within 30
days of MitraClip procedure. Despite advanced disease and co-morbidities, 94% were4 j TCT Abstracts/Valvular disease - Aortic: Balloon Aortic Valvuloplasty
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMdischarged home from the procedure. At 1 year post-MitraClip, CRT non-responders
showed improvements from baseline in clinical and functional measures (Table)
including a 27% reduction in rate of HF hospitalizations.Table 1. Outcomes of Percutaneous Reduction of MR in Symptomatic CRT
Patients
Outcomes Measures
CRT Non-
Responders (N¼48)
Freedom from death at 1 year 76%
Freedom from MR 2+ in surviving patients at 1 year 76%
LVEF at 1 year 38 10%
Improvement in LVEDV at 1 year -12  37 ml (n¼18)
Improvement in LVIDd at 1 year -0.3  0.4 cm
(n¼21)
Improvement in LVIDs at 1 year -0.2  0.6 cm
(n¼20)
% patients with NYHA Class III/IV: Baseline/ 1 year 100%/ 12%
Improvement in SF-36 QoL Physical Component Summary
at 1 year
7.4  9.6 points
(n¼24)
Improvement in SF-36 QoL Mental Component Summary at
1 year
9.2  7.9 points
(n¼24)
HF hospitalization rate per patient-year of follow-up (1 year
pre-procedure/ 1 year post-procedure)
0.92/ 0.67
n ¼ number of paired measurements
Table 1. Baseline characteristics.
Functional Mitral
Regurgitation
p Value
Ischemic
Non-
ischemic
n¼65 n¼46
Age, yrs 779 7314 0.21
Male 50 (77) 19 (41) <0.01
Congestive Heart Failure 31 (48) 29 (63) 0.13
NYHA functional class III or IV 63 (97) 41 (89) 0.103
Society of Thoracic Surgeons Score, % 12.37.4 10.18.2 0.047
Left Ventricular Ejection Fraction, % 4215 4119 0.62
Left Ventricular End Diastolic Dimension,
mm
439 4512 0.42
Mitral Regurgitation grade 3+ or 4+ 65 (100) 46 (100)Conclusions: MitraClip reduced MR and improved symptoms in EVEREST II high
risk FMR patients who had persistent symptomatic MR after CRT. These results are
consistent with the broader experience of MitraClip in high risk patients. The ongoing
COAPT trial will provide insight into the effectiveness of MitraClip in FMR patients
with HF who are refractory to optimal standard of care including CRT. Study funded
by Abbott Vascular.
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Background: Percutaneous mitral valve repair using the transcatheter MitraClip
device is a novel therapy recently FDA approved for patients with severe degenerative
mitral regurgitation (DMR) who are at prohibitive risk for surgery. We herein report
the results of an ongoing single-center post-market series in the United States.
Methods: Patients were screened with transthoracic (TTE) and transesophageal
echocardiography (TEE). Between November of 2013 and April of 2014, 97 patients
presented with severe (4+) DMR. Mitral valve surgery was performed in 76 (78.4%)
of these patients. A multi-disciplinary heart team deemed 21 (21.6%) patients to be
at prohibitive risk for surgery. The MitraClip was deployed under 2- and 3-dimen-
sional TEE, 3D real-time intracardiac echocardiography, and ﬂuoroscopic guidance.
Results: Mean age was 789 years and the average STS score was 12.2%. MitraClip
deployment was successful in 20/21 patients (95.3%); 1 case was unsuccessful due to a
very small left atrium. Two clips were deployed in 3 patients (14.3%). There were no
vascular complications, strokes or procedural deaths. At 30 days there were 2 patients
had died (9.5%), 1 due to respiratory failure at 48 hours and 1 due to a stroke at 3 weeks.
At 1-month follow-up, 17 patients (81.0%) hadGrade 1-2+MR.Left ventricular ejection
fraction was unchanged from baseline to 1 month (mean 40% to 39.5% respectively,
P¼0.80). NYHA class, however, improved signiﬁcantly following intervention with
72.7% of patients being NYHA class I/II at 1 month compared to 12.5% at baseline
(P¼0.0002). Mean BNP levels decreased signiﬁcantly following MitraClip from 1739
pg/ml at baseline to 377.84 pg/ml at 1 month (P¼0.02).
Conclusions: In our experience approximately 1 in 5 patients with severe DMR may
not be eligible for mitral valve surgery. MitraClip edge-to-edge repair is feasible in
such patients, and successfully reduces the severity of MR while improving NYHA
class in the majority. Further studies are needed to examine whether these results are
durable and associated with improved outcomes.
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have been identiﬁed as signiﬁcant predictors of outcome after mitral valve surgery.
Notably, mitral valve surgery tends to worsen TR and RV parameters. However, the
impact of percutaneous mitral valve repair (PMVR) with the MitraClip system in TR
and RV parameters has not been investigated yet.
Methods: We retrospectively assessed TR and RV function parameters on baseline
and follow-up (3-12 months after PMVR) transthoracic echocardiography of 60
consecutive patients (mean age 7211 years, male gender 65.6%) with functional
(57.4%), degenerative (32.8%), or mixed (9.8%) mitral regurgitation (MR), who
underwent PMVR using the MitraClip system. TR was graded on a scale from 1 to 3
according to recommendations of the American Society of Echocardiography. RV
function was analyzed using the fractional area change (FAC) and tricuspid anular
plane systolic excursion (TAPSE).
Results: Acute procedural success of PVMR was achieved in 56 (93%) patients.
Baseline TR was grade 1 in 23 (38%), grade 2 in 18 (30%), and grade 3 in 19 (32%)
patients. TR change (by at least one grade) after PMVR was as follows: decrease in
20 (33%) and increase in 7 (12%) patients (p¼0.039). Systolic RV function (pre/post
FAC and TAPSE) did not change signiﬁcantly. The tricuspid annular diameter also
remained unchanged. There was a trend toward a decrease in maximum pressure
gradient across the tricuspid valve (36 mmHg versus 33 mmHg, p¼0.14) which was
poorly correlated with improvement in TR severity (OR 1.07; p¼0.018). These
ﬁndings were accompanied by a signiﬁcant improvement of NYHA functional class
(p< 0.01).
Conclusions: In patients with severe MR, PMVR using the MitraClip device im-
proves TR. Reduction of TR is associated with the improvement of symptomatic
status after PMVR. A transcatheter TR solution is required for those patients who
experience worsening of TR despite improvement of MR.
TCT-791
The MitraClip Procedure For Functional Mitral Regurgitation: Improved
Outcomes For Both Ischemic and Non-Ischemic Types
Wen Loong Yeow1, Takashi Matsumoto1, Harrison Dinh1, Alfredo Trento1,
Asma Hussaini1, Moody Makar1, Robert Siegel1, Saibal Kar1
1Cedars-Sinai Medical Center, Los Angeles, CA
Background: Outcomes of transcatheter mitral valve repair with the MitraClip in
patients with ischemic or non-ischemic functional mitral regurgitation (FMR) have
not been analyzed separately. Representing the largest single center experience of the
MitraClip procedure in the US, we sought to determine if the outcomes differ between
the two types.
Methods: One hundred and eleven consecutive patients treated with the MitraClip
procedure were analyzed and their outcomes were compared according to the type of
FMR.
Results: Baseline characteristic between the two types were similar except a pre-
ponderance of males and a higher STS score in the ischemic FMR group (Table 1).
Post-procedural reduction of FMR to grade 2+ or less was similar (60 (92%) ischemic
vs 42 (91%) non-ischemic FMR, p¼0.56). Over a median follow-up of 23 months
(IQR 11 to 40months), Kaplan-Meier estimates freedom from all cause death (37% vs
42% at 60-months, p¼0.77), heart failure hospitalization (77% vs 79% at 60-months,
p¼0.44), cardiac surgery (84% vs 95% at 60-months, p¼0.39) and FMR grade 3+ or
greater (79% vs 78% at 60-months, p¼0.99) were similar between ischemic and non-
ischemic FMR respectively.Conclusions: In this ﬁrst-of-a-kind study from the largest single center experience of
the MitraClip procedure in the US for ischemic and non-ischemic FMR, signiﬁcant
and sustained improvements in outcomes were similar for both types. Consequently,
suitable patients with either subtype can be treated effectively.ar disease - Mitraclip B231
